Smoking presents a substantial health and economic burden to people with schizophrenia.
Comorbid use of other substances is common, under-recognised, and associated with a number of serious adverse consequences, such as psychotic relapse and poorer social outcomes.
All patients with schizophrenia need to be screened for substance misuse.
Effective interventions involve integrated, modified pharmacological and psychosocial strategies.
- 1. George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000; 157: 1835-1842.
- 2. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212-217.
- 3. Cantor-Graae E, Nordstrom LG, McNeil TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 2001; 48: 69-82.
- 4. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res 1999; 35 Suppl: S93-S100.
- 5. Fowler IL, Carr VJ, Carter NT, Lewin TJ. Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull 1998; 24: 443-455.
- 6. Chick J, Cantwell R, editors. Seminars in alcohol and drug misuse. London: Gaskell; 1994.
- 7. Woody G, Schuckit M, Weinrieb R, Yu E. A review of the substance use disorders section of the DSM-IV. Psychiatr Clin North Am 1993; 16: 21-32.
- 8. Krystal JH, D'Souza DC, Madonick S, Petrakis IL. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophr Res 1999; 35 Suppl: S35-S49.
- 9. Lambert T, Castle DJ. Pharmacological approaches to the management of schizophrenia. Med J Aust 2003; 178 Suppl May 5: S57-S61.<eMJA full text>
- 10. Spencer C, Castle D, Michie PT. Motivations that maintain substance use among individuals with psychotic disorders. Schizophr Bull 2002; 28: 233-247.
- 11. McNeill A. Smoking and mental health: a review of the literature. SmokeFree London Programme, December 2001. Available at: http://www.ash.org.uk/html/policy/menlitrev.html (accessed Jan 2003).
- 12. Peters MJ, Morgan LC. The pharmacotherapy of smoking cessation. Med J Aust 2002; 176: 486-490. <eMJA full text>
- 13. Smith J, Hucker S. Schizophrenia and substance abuse. Br J Psychiatry 1994; 165: 13-21.
- 14. Drake RE, Mueser KT. Psychosocial approaches to dual diagnosis. Schizophr Bull 2000; 26: 105-118.
- 15. Ziedonis DM, D'Avanzo K. Schizophrenia and substance abuse. In: Kranzler HR, Rounsaville BJ, editors. Dual diagnosis and treatment: substance abuse and comorbid medical and psychiatric disorders. New York: Marcel Dekker, 1998: 427-465.
- 16. O'Neill MM. Countertransference and attitudes in the context of clinical work with dually diagnosed patients. In: Solomon J, Zimberg S, Shollar E, editors. Dual diagnosis: evaluation, treatment, training, and program development. New York: Plenum Press, 1993: 127-146.
- 17. George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 2002; 52: 53-61.
- 18. Miller W, Rollnick S. Motivational interviewing: preparing people to change addictive behaviours. New York: Guildford, 1991.
- 19. Prochaksa JO, DiClemente CC, Norcross JC. In search of how people change: applications to addictive disorders. Am Psychol 1992; 47: 1102-1114.
- 20. Marlatt G, Gordon J. Relapse prevention: maintenance strategies in the treatment of addictive behaviours. New York: Guildford Press, 1985.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.